Possible Pharmacological Effect of Quercetin in the Management of Hyperuricemia - Results From Real-life Clinical Studies

Liaquat University of Medical & Health Sciences

Status: Completed

Conditions: Hyperuricemia

Treatments: Dietary Supplement: Quevir® (Quercetin Phytosome®); Dietary Supplement: Bactoblis®

Study type: Observational

Funder types: Other

Identifiers

NCT06652035

88_18.01.2023_QuercetinFit - A

Details and patient eligibility

About

Quercetin, a natural flavonoid found in various fruits and vegetables, has gained attention for its potential role in managing hyperuricemia. Emerging evidence suggests that quercetin may reduce plasma uric acid levels by inhibiting xanthine oxidase, an enzyme responsible for uric acid production. Additionally, its anti-inflammatory and antioxidant properties could help mitigate the oxidative stress and inflammation associated with hyperuricemia. As a result, quercetin supplementation offers a promising avenue for therapeutic intervention in conditions like gout and other uric acid-related disorders.

Full description

In the present retrospective cross-sectional observational study, the investigators assessed the potential pharmacological effect of supplemental quercetin on the plasma uric acid levels of health adults. These participants visited nutritional clinics in Italy during the Coronavirus disease (COVID-19) pandemic for general health check-up in real-life to enhance their immune system with supplements aimed at providing additional protection against COVID-19 infection. The supplements, either quercetin or probiotic Streptococcus salivarius K12 (BLIS K12), were advised randomly to the participants for 90 days, tailored to individual needs and in the absence of any pre-defined criteria.

Enrollment: 161 patients

Sex: All

Ages: 18 to 65 years old

Volunteers: Accepts Healthy Volunteers

Inclusion criteria

• Healthy adults
• BMI between 18.5 and 29.9 kg/m²
• Non-smoker
• Consumtion of less than 3 units of alcohol per day

Exclusion criteria

• • Plasma uric acid concentrations above 7 mg/dL
• Diagnosis of endocrinological, metabolic, oncological, neurological, or bowel inflammatory disease diseases, gout, kidney stones

Trial design

161 participants in 2 patient groups

Supplemental Quercetin group

Description:

These participants received oral 500 mg Quevir® (Quercetin Phytosome®) tablet, twice a day for 90 days. Each Quevir® tablet contains 200 mg pure Quercetin.

Treatment:

Dietary Supplement: Quevir® (Quercetin Phytosome®)

Supplemental Probiotic Strptococcus salivarius K12 (ATCC BAA-1024) group

Description:

These participants received orally dissolving Bactoblis® tablet, once daily before bedtime for 90 days. Each Bactoblis® tablet contains at least 1x10⁹ CFU of probiotic S. salivarius K12 (ATCC BAA-1024).

Treatment:

Dietary Supplement: Bactoblis®